The development of regenerative dentistry and implantology in recent years has been accompanied by the active introduction of new bone graft materials, which, in turn, increases the requirements for their safety, efficacy, and ethical justification in preclinical studies. In this context, regulatory documents that establish unified standards for evaluating medical devices take on particular significance. The finalization of the updated guidance by the U.S. Food and Drug Administration (FDA), dedicated to the use of animal studies for dental bone graft materials, reflects the regulator’s aim to adapt oversight mechanisms to contemporary scientific and technological realities while simultaneously supporting innovation and reducing reliance on animal testing.
In August 2025, the FDA officially published the final version of the guidance regulating the conduct and interpretation of animal studies for devices and materials used in dental bone grafting. The document serves as an update to the 2005 recommendations and was developed to reflect current expert review practices, enhance the consistency of regulatory decisions, and streamline the process of reviewing product market authorization applications. A draft version of the guidance was presented to the professional community in March 2024, allowing for stakeholder feedback to be incorporated before the final version was approved.
The new guidance includes detailed recommendations on the design and conduct of preclinical studies that can be used to demonstrate the compliance of dental bone graft materials with specific FDA control requirements. In particular, it emphasizes the need to select anatomical models that closely approximate the intended intraoral application or to employ so-called “worst-case scenario” bone defect models to evaluate the safety and functional characteristics of the material.
FDA representatives, in a comment to Dental Tribune International, noted that the document is intended to serve as a practical resource for manufacturers developing new or innovative biomaterials. The guidance helps provide a structured approach to assessing the safety and performance characteristics of devices as part of pre-market submissions. At the same time, for companies that continue to use animal studies, the recommendations aim to ensure the adequacy and scientific validity of the in vivo data obtained.
A key element of the updated document is the support for the principles of the 3Rs—replacement, reduction, and refinement of animal use in scientific research. The FDA emphasizes that integrating safety assessment, functional characterization, and biocompatibility evaluation within a single study can significantly reduce the number of animals used. Furthermore, the regulator encourages manufacturers to engage in dialogue with the agency if they intend to use validated alternative methods that do not involve animal models.
The relevance of the updated guidance is largely driven by the scale of bone grafting applications in modern dentistry. With the advancement of implant therapy and regenerative medicine, bone grafting procedures have become a routine part of clinical practice. According to research, up to half of all implant-related interventions involve the use of bone grafts, which globally corresponds to approximately 2.2 million procedures annually. Although autografts remain the “gold standard,” xenogenic and allogenic grafts, including materials derived from bovine and porcine bone, are widely used in clinical practice.
In light of such extensive application, it is particularly crucial for new materials to undergo rigorous, yet rational and ethically justified, preclinical evaluation. The finalization of the FDA guidance aims precisely to achieve this balance, ensuring patient protection while simultaneously lowering barriers to the implementation of innovative solutions in the field of dental biomaterials.
The updated FDA guidance on animal studies for dental bone graft materials represents a significant step in the evolution of the regulatory approach to evaluating medical devices. It reflects contemporary scientific perspectives, supports the advancement of innovative biomaterials, and emphasizes the importance of ethical principles in preclinical research. For manufacturers and researchers, the document creates a more transparent and predictable regulatory environment, while for clinicians and patients, it provides additional assurances of the safety and efficacy of the materials used. In the long term, such initiatives foster the sustainable development of regenerative dentistry, where technological progress is coupled with a responsible approach to scientific and ethical standards.
Modern dentistry is increasingly developing through the synthesis of science, clinical practice, and educational initiatives, shaping a new model of
Implantology in the 21st century is developing as one of the most dynamic fields of dentistry, combining surgical techniques, digital
OTEXE.COM uses cookies to personalize the services and improve the usability of the site. If you do not want to use cookies, please disable them in your browser settings.
